CDI 873
Alternative Names: CDI-873Latest Information Update: 07 Jun 2022
Price :
$50 *
At a glance
- Originator Cocrystal Pharma Inc
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 01 Jun 2022 Cocrystal Pharma and National Institute of Allergy and Infectious Diseases (NIAID) enters a Non-Clinical Evaluation Agreement (NCEA) for CDI 873 for COVID-2019 infections
- 27 Jan 2022 Cocrystal Pharma plans a phase I clinical trial for COVID-2019 infections, in 2022
- 27 Jan 2022 Preclinical trials in COVID-2019 infections in USA, prior to January 2022 (PO)